Bifidobacterium breve B-3 exerts metabolic syndrome-suppressing effects in the liver of diet-induced obese mice: a DNA microarray analysis.
- 2013-09-01
- Beneficial Microbes 4(3)
- S. Kondo
- A. Kamei
- J.‐Z. Xiao
- K. Iwatsuki
- K. Abe
- PubMed: 23666099
- DOI: 10.3920/BM2012.0019
Study Design
- Type
- Clinical Trial
- Population
- Mice with diet-induced obesity
- Methods
- In vivo experiment with gene expression analysis
- Animal Study
Abstract
We previously reported that supplementation with Bifidobacterium breve B-3 reduced body weight gain and accumulation of visceral fat in a dose-dependent manner, and improved serum levels of total cholesterol, glucose and insulin in a mouse model of diet-induced obesity. In this study, we investigated the expression of genes in the liver using DNA microarray analysis and q-PCR to reveal the mechanism of these anti-obesity effects in this mouse model. Administration of B. breve B-3 led to regulated gene expression of pathways involved in lipid metabolism and response to stress. The results indicate that these regulations in the liver are related to the anti-metabolic syndrome effects of B. breve B-3.